biote Corp. (NASDAQ:BTMD) Short Interest Update

biote Corp. (NASDAQ:BTMD) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,110,000 shares, a decrease of 5.9% from the August 31st total of 1,180,000 shares. Approximately 3.7% of the shares of the stock are sold short. Based on an average daily volume of 246,800 shares, the days-to-cover ratio is presently 4.5 days.

Insider Buying and Selling

In other biote news, CFO Robert Charles Peterson sold 11,376 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $7.57, for a total transaction of $86,116.32. Following the sale, the chief financial officer now owns 32,874 shares of the company’s stock, valued at $248,856.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 13.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On biote

A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its position in shares of biote by 1,016.6% during the second quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock worth $4,931,000 after acquiring an additional 600,956 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of biote by 251.8% in the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock worth $1,442,000 after purchasing an additional 138,200 shares during the period. Bandera Partners LLC boosted its stake in shares of biote by 7.5% in the 4th quarter. Bandera Partners LLC now owns 1,832,732 shares of the company’s stock valued at $9,054,000 after purchasing an additional 127,410 shares during the last quarter. Sanders Morris Harris LLC acquired a new stake in shares of biote during the second quarter worth $585,000. Finally, GDS Wealth Management bought a new position in biote during the second quarter worth $432,000. Institutional investors own 21.68% of the company’s stock.

biote Trading Up 4.0 %

NASDAQ:BTMD opened at $5.67 on Monday. The stock’s 50-day moving average is $6.37 and its 200-day moving average is $6.42. biote has a 1-year low of $3.65 and a 1-year high of $8.44. The stock has a market cap of $351.74 million, a P/E ratio of 51.55 and a beta of 0.94.

biote (NASDAQ:BTMD) last posted its earnings results on Thursday, August 8th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $49.17 million for the quarter, compared to analyst estimates of $50.40 million. biote had a net margin of 3.67% and a negative return on equity of 20.92%. As a group, equities analysts forecast that biote will post 0.52 EPS for the current year.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.